Roche €1bn leads corporates’ charge to sub-curve pricing

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Roche €1bn leads corporates’ charge to sub-curve pricing

Superlatives failed bankers today and they just had to laugh as five companies charged into the European bond market and all achieved the highly successful issues that have become the norm in recent weeks.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts
Gift this article